Phase II study with Ga101-DHAP as induction therapy in relapsed/refractoryDiffuse Large B-cell Lymphoma (DLBCL) patients before High-Dosechemotherapy BEAM with autologous stem cell transplantation (ASCT).

• Conditions: Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen.; MedDRA version: 17.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851; Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

• Registration Number: EUCTR2013-004014-17-IT
• Lead Sponsor: Fondazione Italiana Linfomi ONLUS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-06-04
• Last Update Posted: 10 July 2015

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.18= Age < 65
2.Relapsed/refractory disease after receiving one line of standard R-CHOP like chemotherapy
3.Diffuse Large B-cell Lymphoma at relapse. Patient has to be re-biopsied prior study entry. This is particularly recommended if relapse is over 1 year from previous complete remission. If this is harmful for the patient, the patient can be enrolled if archivial tumor sample and block from first diagnosis are available.
4.Measurable and/or evaluable disease
5.Any Ann Arbor stage and IPI group at relapse
6.Performance status < 2 according to ECOG scale unless due to lymphoma
7.No Central Nervous System (CNS) disease (meningeal and/or brain involvement by lymphoma)
8.Adequate haematological counts: ANC > 1.5 x 109/L, Hgb > 10.5 g/dl (transfusion independent), Platelet count > 75 x 109/L (transfusion independent), with the exception of cytopenia due to lymphoma bone marrow involvement
9.Normal liver function (ALP, AST, ALT, GGT, conjugated bilirubin total < 2 x ULN) if not related to lymphoma
10.Normal kidney function (creatinine clearance > 45 ml/min)
11.Cardiac ejection fraction > 50% (MUGA scan or echocardiography)
12.Normal lung function
13.Absence of active infections
14.Non peripheral neuropathy or active neurological non neoplastic disease of CNS
15.Non major surgical intervention prior 3 months to randomization if not due to lymphoma and/or not other disease life-threatening that can compromise chemotherapy treatment
16.Disease free of prior malignancies other than lymphoma for > 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
17.Life expectancy > 6 months
18.No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
19.Written informed consent
20.Women must be:
-postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
-surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
-abstinent (at the discretion of the investigator/per local regulations), or
-if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 12 months after terminating treatment.
21.Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
22.Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 78
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Diagnosis of Lymphoblastic Lymphoma, Burkitt Lymphoma, Non Hodgkin Lymphoma CD20 negative, Mantle Cell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma
2.Age = 65 years
3.Patients ineligible to high-dose chemotherapy
4.Performance status > 2 according to ECOG scale if not due to lymphoma
5.Patients who previously received GA101 (obinutuzumab) are excluded.
6.Patient has known or suspected hypersensitivity or intolerance to Rituximab
7.Patient has received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
8.CNS disease (meningeal and/or brain involvement by lymphoma)
9.History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
10.Positive test results for chronic hepatitis B infection (defined as positive HBsAg serology)
Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.
11.Positive test results for hepatitis C (HCV antibody serology testing)
Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
12.Known history of HIV seropositive status
For patients with unknown HIV status, HIV testing will be performed at screening if required by local regulations.
13.Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
14.Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
15.Cardiac ejection fraction < 45% (MUGA scan or echocardiography)
16.Creatinine clearance < 45 ml/min
17.Presence of major neurological disorders
18.Active infection
19.Major surgical intervention prior 3 months to randomization if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment
20.Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
21.Life expectancy < 6 months
22.Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
23.If female, the patient is pregnant or breast-feeding.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Secondary Objective: •Overall Response Rate (ORR) prior to consolidation with BEAM and ASCT <br>•Progression free survival (PFS)<br>•Overall Survival (OS)<br>•Feasibility and toxicity <br>•The hematopoietic cell mobilization <br>•The rate of patients actually proceeding to ASCT.<br>;Primary end point(s): The complete response rate (CR) evaluated by PET scan after four cycles of GA101-DHAP before ASCT according to Cheson criteria.;Timepoint(s) of evaluation of this end point: After 4 cycles of treatment with GA101-DHAP.;Main Objective: Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL. <br>Primary objective is to assess whether the treatment achieves an absolute increase of the CR proportion of at least 20% (from 30% to 50%) with respect to the standard treatment. <br>